Closely held Beacon Therapeutics announced the appointment of Dr. Daniel Chung as chief medical officer (CMO), effective immediately.
Dr. Chung brings more than three decades of experience in ophthalmology, academic research, and gene therapy development to the role. Most recently, he served as CMO at SparingVision, a clinical-stage genomic medicine company.
Lance Baldo, MD, CEO of Beacon, said, “We are thrilled to welcome Dan to our leadership team. He brings deep clinical and translational expertise in developing gene therapies for retinal diseases and has demonstrated an unwavering commitment to patients and the clinical community supporting blinding diseases. His appointment comes at a critical time for Beacon as we approach the completion of enrolment of our registrational Phase 2/3 VISTA trial.”
Dr. Chung remarked, “Beacon Therapeutics is making great progress, and I look forward to being part of an inspired team with its unique approach to advancing gene therapy to address rare and prevalent retinal diseases. X-linked retinitis pigmentosa is a devastating disease with no currently approved treatment. I am greatly encouraged by the data from the Phase 2 DAWN trial, and look forward to applying my expertise to advance laru-zova through the regulatory process, one step closer to approval, and potentially treating patients living with progressive vision loss.”
